title: Efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable breast cancer: a retrospective analysis.
abstract: BACKGROUND
  Given the use of tamoxifen as standard treatment for hormone receptor-positive breast cancer, the use of toremifene as an adjuvant endocrine therapy has not been widely examined. The present retrospective study compared the efficacy and safety of toremifene and tamoxifen in the treatment of operable hormone receptor-positive breast cancer in premenopausal women.
  
  
  METHODS
  Premenopausal patients with hormone receptor- positive operable breast cancer were eligible. Enrolled patients (n = 1847) received either 60 mg toremifene (n = 396) or 20 mg tamoxifen (n = 1451) daily for a minimum of 5 years after surgery. Disease-free survival (dfs) was the primary endpoint. Overall survival (os) and time to distant recurrence were secondary endpoints.
  
  
  RESULTS
  Treatment with toremifene and tamoxifen resulted in no between-group differences in dfs (p = 0.659) or os (p = 0.364). Mean dfs was 10.3 years for both groups. Mean os was 11.2 years for the toremifene group and 11.1 years for tamoxifen group. The 5-year dfs rate was 87.0% in the toremifene group and 85.0% in the tamoxifen group. The 5-year survival rate was 94.3% in the toremifene group and 93.5% in the tamoxifen group. Adverse events rates were similar in the two groups, with the exception of irregular menses, which occurred at a higher rate in the tamoxifen group than in the toremifene group (10.0% vs. 6.3%, p = 0.025).
  
  
  CONCLUSIONS
  In this retrospective study, the efficacy and safety profiles of toremifene and tamoxifen for the treatment of operable hormone receptor-positive breast cancer in premenopausal women were similar.
authors.affiliation: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, PR China.
authors.forename: T
authors.initials: T
authors.lastname: Qin
authors.forename: Z Y
authors.initials: ZY
authors.lastname: Yuan
authors.forename: R J
authors.initials: RJ
authors.lastname: Peng
authors.forename: Y D
authors.initials: YD
authors.lastname: Zeng
authors.forename: Y X
authors.initials: YX
authors.lastname: Shi
authors.forename: X Y
authors.initials: XY
authors.lastname: Teng
authors.forename: D G
authors.initials: DG
authors.lastname: Liu
authors.forename: B
authors.initials: B
authors.lastname: Bai
authors.forename: S S
authors.initials: SS
authors.lastname: Wang
keywords: Tamoxifen; adjuvant endocrine therapy; breast cancer; premenopausal; toremifene
references.citation: Clin Cancer Res. 2005 Jul 1;11(13):4741-8
references.pmid: 16000569
references.citation: Ann Oncol. 2004 Dec;15(12):1749-59
references.pmid: 15550579
references.citation: J Clin Oncol. 2000 Oct 15;18(20):3487-94
references.pmid: 11032589
references.citation: Acta Ophthalmol Scand. 2003 Oct;81(5):495-9
references.pmid: 14510798
references.citation: Clin Breast Cancer. 2006 Feb;6 Suppl 2:S36-40
references.pmid: 16595024
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Breast Cancer Res. 2007;9(6):115
references.pmid: 18190722
references.citation: BMC Cancer. 2012 May 01;12:161
references.pmid: 22548922
references.citation: BMC Cancer. 2006 Jul 20;6:194
references.pmid: 16857060
references.citation: Breast. 2006 Apr;15(2):142-57
references.pmid: 16289904
references.citation: Cancer. 2010 May 15;116(10):2307-15
references.pmid: 20209619
references.citation: Int J Cancer. 2002 Jul 20;100(3):337-41
references.pmid: 12115550
references.citation: Breast Cancer Res Treat. 2010 Jan;119(1):193-200
references.pmid: 19350387
references.citation: N Engl J Med. 1998 Nov 26;339(22):1609-18
references.pmid: 9828250
references.citation: Ann Oncol. 2007 Jul;18(7):1133-44
references.pmid: 17675394
references.citation: Breast Cancer Res Treat. 1999 Jul;56(2):133-43
references.pmid: 10573106